Introduction of a logo as additional risk minimisation material - A benefit or disadvantage? discussion session on 16 December 2024

Fimea will organise a virtual discussion session for marketing authorisation holders or their representatives titled Introduction of a logo as additional risk minimisation material - A benefit or disadvantage? on 16 December 2024 at 9.30–11.00 (Teams meeting). 

The topic of the event is discussion on the necessity of a label or logo as additional risk minimisation material.

Identification of risk minimisation materials is particularly important for healthcare professionals when treating patients. It has been observed that not all health care operators are sufficiently aware of risk minimisation materials or cannot point out risk minimisation-related messages when these are mixed in with other information.

Fimea representatives will hold introductory speeches at the beginning of the event. The Howspace platform will also be used to assist in discussion. 

Please register for the event no later than 9 December. 

Advance registration will be required for the event. Register using the Webropol link below no later than 9 December. The participation link will be sent by email well in advance of the event to those who have registered.

Registration (Webropol) 

Please join us!

Guideline on good pharmacovigilance practices (GVP) Module XVI – Risk minimisation measures (Rev 3) (pdf, EMA)

Enquiries:

[email protected],
Jaana Santaholma, Head of Division, Pharmacovigilance Division, tel. +358 29 522 3414  
Piia Vuorela, Director, Safety and Effectiveness, tel. +358 29 522 3510
Email addresses are in the format [email protected].